SCHEMBL25345347

SCHEMBL25345347

COCCOc1cc(F)ccc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 1/20 0.49
PTK2B Q14289 1/20 0.49
FFAR4 Q5NUL3 1/20 0.46
LTB4R Q15722 1/20 0.43
LTB4R2 Q9NPC1 1/20 0.43
HRH2 P25021 1/20 0.42
RARA P10276 1/20 0.42
RARB P10826 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CYP2C9 P11712 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KEAP1 Q14145 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 1/20 0.40
PRKAB2 O43741 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3846283 0.88 LMNA (0.51) ALDH1A1KMT2AFFAR4KDM4EHTT
SCHEMBL1505106 0.88 ALDH1A1 (0.49) ALDH1A1KMT2APTK2BHRH2NPC1
SCHEMBL25344842 0.86 FFAR4 (0.57) ALDH1A1KMT2AFFAR4NPC1RAB9A
SCHEMBL27009298 0.84 ALDH1A1 (0.54) ALDH1A1KMT2APTK2BRARARARB
SCHEMBL12466431 0.84 ALDH1A1 (0.47) ALDH1A1KMT2APTK2BFFAR4LTB4R
SCHEMBL25342402 0.84 DHODH (0.39) ALDH1A1KMT2APTK2BFFAR4HRH2
SCHEMBL20471860 0.83 PTPN11 (0.52) KMT2ALTB4RLTB4R2RARARARB
SCHEMBL20982590 0.83 CA12 (0.50) ALDH1A1KMT2APTK2BHTT
SCHEMBL25527330 0.83 ALDH1A1 (0.46) ALDH1A1KMT2APTK2BFFAR4LTB4R
SCHEMBL15048810 0.82 TSHR (0.51) KMT2AFFAR4KEAP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025034858-A1 FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2025-02-13 WO disclosed
EP-4476204-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS Theras, Inc. (US) 2024-12-18 EP disclosed
CN-118946555-A Compounds having T-structures formed by at least four rings for use in the treatment of cancer and other indications 瑟拉斯有限公司 2024-11-12 CN disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed